Answers are grounded in this paper and cite their sources.
The thiazolidinediones pioglitazoneand rosiglitazone were introducedinto global markets in 1999–2000; we now have over 10 years of experience with them. The safety issues that it was fashionable to focus on at that time were abnormalities of liver function as a result of the rare but serious side effects of troglitazone, the thiazolidinedione then on the market. This turned out to be ir-relavent for other thiazolidinediones without the antioxidant structure of troglitazone and has long since been forgotten in clinical practice. Many practicing clinicians felt con-cern, however, with the mechanisms of action of these drugs, namely to influence
No takes yet. Share an insight, caveat, or question.
Philip Home (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: